Compared with placebo or other interventions, GLP-1 receptor agonists use showed an association with an increased risk of overall thyroid disorders (RR 1.28, 95% CI 1.03-1.60)
The triple action is designed to reduce appetite, slow gastric emptying, improve insulin response, and increase energy expenditure all at once
I statistics were used to assess heterogeneity, and Eggers and Beggs tests were used to evaluate publication bias
It explains concepts like peak concentration, trough levels, and accumulation in plain language with visual examples
Most people panic in Phase 2 or Phase 3
Guided Progress As treatment progresses, your provider monitors results and adjusts dosing to ensure safe and effective progress